NO960619D0 - Antipsykotisk fremgangsmåte - Google Patents

Antipsykotisk fremgangsmåte

Info

Publication number
NO960619D0
NO960619D0 NO960619A NO960619A NO960619D0 NO 960619 D0 NO960619 D0 NO 960619D0 NO 960619 A NO960619 A NO 960619A NO 960619 A NO960619 A NO 960619A NO 960619 D0 NO960619 D0 NO 960619D0
Authority
NO
Norway
Prior art keywords
mammal
antipsychotic method
antipsychotic
schizophrenia
sulphur
Prior art date
Application number
NO960619A
Other languages
English (en)
Other versions
NO312706B1 (no
NO960619L (no
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO960619D0 publication Critical patent/NO960619D0/no
Publication of NO960619L publication Critical patent/NO960619L/no
Publication of NO312706B1 publication Critical patent/NO312706B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO19960619A 1993-08-19 1996-02-16 Anvendelse av tiadiazolforbindelser til fremstilling av farmasöytiske preparater for behandling av schizofreni ogschizofreniforme sykdommer NO312706B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19
PCT/DK1994/000305 WO1995005174A1 (en) 1993-08-19 1994-08-15 Antipsychotic method

Publications (3)

Publication Number Publication Date
NO960619D0 true NO960619D0 (no) 1996-02-16
NO960619L NO960619L (no) 1996-04-18
NO312706B1 NO312706B1 (no) 2002-06-24

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960619A NO312706B1 (no) 1993-08-19 1996-02-16 Anvendelse av tiadiazolforbindelser til fremstilling av farmasöytiske preparater for behandling av schizofreni ogschizofreniforme sykdommer

Country Status (23)

Country Link
EP (1) EP0734259B1 (no)
JP (1) JP3126736B2 (no)
KR (1) KR100360575B1 (no)
CN (1) CN1087936C (no)
AT (1) ATE218864T1 (no)
AU (1) AU701292B2 (no)
CA (1) CA2169839C (no)
CZ (1) CZ285030B6 (no)
DE (1) DE69430816T2 (no)
DK (1) DK0734259T3 (no)
ES (1) ES2177581T3 (no)
FI (2) FI960747A (no)
HU (1) HU221729B1 (no)
IL (1) IL110708A (no)
NO (1) NO312706B1 (no)
NZ (2) NZ271311A (no)
PT (1) PT734259E (no)
RU (1) RU2191580C2 (no)
SG (1) SG55071A1 (no)
TW (1) TW442284B (no)
UA (1) UA63876C2 (no)
WO (1) WO1995005174A1 (no)
ZA (1) ZA946324B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5672709A (en) * 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
ATE191344T1 (de) * 1994-10-31 2000-04-15 Lilly Co Eli Tetrahydropyridin oxadiazol- oder -thiadiazol- verbindung zur behandlung von angstzuständen
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
DK0821955T3 (da) * 1996-08-01 2002-03-18 Lilly Co Eli Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
JP2002500651A (ja) * 1997-05-29 2002-01-08 ハー・ルンドベック・アクティーゼルスカブ 精神***病及び精神病の治療方法
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
NZ773719A (en) 2018-09-28 2022-07-29 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
UA63876C2 (en) 2004-02-16
CZ285030B6 (cs) 1999-05-12
KR960703592A (ko) 1996-08-31
FI20050461A (fi) 2005-04-29
NZ336597A (en) 2001-02-23
HU9600364D0 (en) 1996-04-29
SG55071A1 (en) 1998-12-21
DE69430816T2 (de) 2002-12-19
CZ42696A3 (en) 1996-11-13
CA2169839C (en) 2002-06-11
EP0734259A1 (en) 1996-10-02
DK0734259T3 (da) 2002-09-30
HUT75111A (en) 1997-04-28
FI960747A0 (fi) 1996-02-19
IL110708A (en) 1998-12-06
AU7490294A (en) 1995-03-14
FI960747A (fi) 1996-04-17
NZ271311A (en) 1999-09-29
EP0734259B1 (en) 2002-06-12
CN1133008A (zh) 1996-10-09
ES2177581T3 (es) 2002-12-16
NO312706B1 (no) 2002-06-24
ATE218864T1 (de) 2002-06-15
CA2169839A1 (en) 1995-02-23
DE69430816D1 (de) 2002-07-18
JPH09501658A (ja) 1997-02-18
TW442284B (en) 2001-06-23
PT734259E (pt) 2002-11-29
HU221729B1 (hu) 2002-12-28
JP3126736B2 (ja) 2001-01-22
WO1995005174A1 (en) 1995-02-23
CN1087936C (zh) 2002-07-24
NO960619L (no) 1996-04-18
KR100360575B1 (ko) 2003-03-10
ZA946324B (en) 1996-02-19
AU701292B2 (en) 1999-01-21
IL110708A0 (en) 1994-11-11
RU2191580C2 (ru) 2002-10-27

Similar Documents

Publication Publication Date Title
FI20050461A (fi) Antipsykoottinen käyttö
EP0604641A4 (en) COMPOSITION CONTAINING AMINO DERIVATIVES OR RELATED TO BENZOIC ACID AMINES AND USES THEREOF, INCLUDING IN THE TREATMENT OF INFLAMMATORY DISEASES.
EP0613883A4 (en) HYDROXAMIC ACID DERIVATIVE.
DE69902634T2 (de) Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien
FI903215A0 (fi) Heteroarylamino- och heteroaryloxipyridinaminer och till desa hoerande foereningar, foerfarande foer deras framstaellning samt deras anvaendning som laekemedel.
ES8706149A1 (es) Procedimiento para preparar 4h-1-benzopiran-4-onas
DK0714394T3 (da) Antipsykotisk fremgangsmåde
BR9611472A (pt) Compostos de di-terc-butilfenol contendo enxofre úteis como agentes antiinflamatórios
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
NO20003481L (no) FremgangsmÕte for behandling av COPD
DE68911237D1 (de) Nichtionische Trijodbenzin-Verbindungen und diese enthaltende Kontrastmittel.
ES2123728T3 (es) Derivados de pirrolo-pirazina de actividad 5-ht3.
ATE118209T1 (de) Pyridin-3-percarboxylsäure monopersulfat.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

MM1K Lapsed by not paying the annual fees